Fyntechnical Innovations Inc — Financial Data
Annual figures from SEC EDGAR XBRL filings (10-K)
These figures are extracted directly from XBRL-tagged financial statements that Fyntechnical Innovations Inc filed with the SEC as part of its annual 10-K reports. XBRL (eXtensible Business Reporting Language) is a structured data format the SEC requires for machine-readable financial disclosures. Values shown are as reported — negative figures indicate a loss and are shown in red.
Revenue
Total revenue from all business activities — the top line of the income statement. Represents all money earned before any expenses are deducted.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2024 | Dec 31, 2024 | $0 | Apr 15, 2025 |
| FY2024 | Dec 31, 2023 | $0 | Apr 15, 2025 |
| FY2023 | Dec 31, 2022 | $0 | Apr 15, 2024 |
Net Income
The bottom-line profit — what remains after all operating expenses, interest, taxes, and other costs are deducted. A negative value means the company reported a net loss for the year.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2024 | Dec 31, 2024 | ($8.43M) | Apr 15, 2025 |
| FY2024 | Dec 31, 2023 | ($1.49M) | Apr 15, 2025 |
| FY2023 | Dec 31, 2022 | ($1.23M) | Apr 15, 2024 |
Operating Income
Profit from core business operations before interest expense and income taxes (also known as EBIT). Excludes non-operating items, making it a cleaner measure of operational efficiency than net income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2024 | Dec 31, 2024 | ($798.3K) | Apr 15, 2025 |
| FY2024 | Dec 31, 2023 | ($923.8K) | Apr 15, 2025 |
| FY2023 | Dec 31, 2022 | ($3.17M) | Apr 15, 2024 |
R&D Expense
Spending on research and development activities — developing new products, improving existing ones, or conducting basic research. High R&D relative to revenue is common in technology and pharmaceutical companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2024 | Dec 31, 2024 | $71.3K | Apr 15, 2025 |
| FY2024 | Dec 31, 2023 | $0 | Apr 15, 2025 |
Operating Cash Flow
Cash generated from core business operations — a more reliable measure of financial health than net income because it strips out non-cash items like depreciation and one-time charges.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2024 | Dec 31, 2024 | ($196.0K) | Apr 15, 2025 |
| FY2024 | Dec 31, 2023 | ($191.8K) | Apr 15, 2025 |
| FY2023 | Dec 31, 2022 | ($189.3K) | Apr 15, 2024 |
Total Assets
The total value of everything the company owns or controls — cash, investments, receivables, property, equipment, and intangibles. Reported as of fiscal year end.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2024 | Dec 31, 2024 | $75.9K | Apr 15, 2025 |
| FY2024 | Dec 31, 2023 | $68.5K | Apr 15, 2025 |
| FY2023 | Dec 31, 2022 | $308.4K | Apr 15, 2024 |
Total Liabilities
All financial obligations owed to outside parties — including debt, accounts payable, accrued expenses, and deferred revenue. Subtracting liabilities from total assets gives stockholders' equity.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2024 | Dec 31, 2024 | $11.08M | Apr 15, 2025 |
| FY2024 | Dec 31, 2023 | $3.63M | Apr 15, 2025 |
| FY2023 | Dec 31, 2022 | $2.66M | Apr 15, 2024 |
Stockholders Equity
The net worth attributable to shareholders: total assets minus total liabilities. Also called book value. Can be negative if liabilities exceed assets, which is common in capital-intensive industries.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2024 | Dec 31, 2024 | ($11.00M) | Apr 15, 2025 |
| FY2024 | Dec 31, 2023 | ($3.56M) | Apr 15, 2025 |
| FY2024 | Dec 31, 2022 | ($2.66M) | Apr 15, 2025 |
| FY2023 | Dec 31, 2021 | ($3.78M) | Apr 15, 2024 |
Goodwill
An intangible asset representing the premium paid above fair value when acquiring another company. A large goodwill balance signals a history of acquisitions at premium prices.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2024 | Dec 31, 2023 | $0 | Apr 15, 2025 |
| FY2023 | Dec 31, 2022 | $0 | Apr 15, 2024 |
Retained Earnings
Cumulative net income kept by the company rather than distributed as dividends. A growing retained earnings balance indicates consistent profitability; a deficit indicates cumulative losses.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2024 | Dec 31, 2024 | ($26.22M) | Apr 15, 2025 |
| FY2024 | Dec 31, 2023 | ($17.79M) | Apr 15, 2025 |
| FY2023 | Dec 31, 2022 | ($16.00M) | Apr 15, 2024 |
EPS (Diluted)
Net income divided by the fully diluted share count — including all potential shares from options, warrants, and convertible instruments. The more conservative and widely cited EPS figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2024 | Dec 31, 2024 | 0 | Apr 15, 2025 |
| FY2024 | Dec 31, 2023 | 0 | Apr 15, 2025 |
Shares Outstanding
Total common shares issued and held by all shareholders, excluding treasury shares. Combined with market price gives market capitalization.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2024 | Dec 31, 2024 | 1.35B | Apr 15, 2025 |
| FY2024 | Dec 31, 2023 | 1.38B | Apr 15, 2025 |
| FY2023 | Dec 31, 2022 | 962.54M | Apr 15, 2024 |